Literature DB >> 2164831

Dose intensity in cancer chemotherapy.

D J Dodwell1, H Gurney, N Thatcher.   

Abstract

Entities:  

Mesh：

Year:  1990        PMID： 2164831      PMCID： PMC1971684          DOI： 10.1038/bjc.1990.178

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  32 in total

1.  Dose intensity analysis of melphalan and prednisone in multiple myeloma.

Authors:  M Palmer; A Belch; J Hanson; L Brox
Journal:  J Natl Cancer Inst       Date:  1988-05-18       Impact factor: 13.506

2.  Randomized dose-response evaluation of etoposide in small cell carcinoma of the lung: a Southeastern Cancer Study Group Trial.

Authors:  S N Wolff; R Birch; P Sarma; F A Greco
Journal:  Cancer Treat Rep       Date:  1986-05

3.  A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma.

Authors:  J Klastersky; J P Sculier; P Ravez; P Libert; J Michel; G Vandermoten; P Rocmans; Y Bonduelle; M Mairesse; T Michiels
Journal:  J Clin Oncol       Date:  1986-12       Impact factor: 44.544

4.  The description of chemotherapy delivery: options and pitfalls.

Authors:  C M Coppin
Journal:  Semin Oncol       Date:  1987-12       Impact factor: 4.929

5.  Autologous bone marrow transplantation for patients with poor-prognosis lymphoma.

Authors:  S C Gulati; B Shank; P Black; J Yopp; B Koziner; D Straus; D Filippa; S Kempin; H Castro-Malaspina; I Cunningham
Journal:  J Clin Oncol       Date:  1988-08       Impact factor: 44.544

6.  Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study.

Authors:  G N Hortobagyi; G P Bodey; A U Buzdar; D Frye; S S Legha; R Malik; T L Smith; G R Blumenschein; H Y Yap; V Rodriguez
Journal:  J Clin Oncol       Date:  1987-03       Impact factor: 44.544

7.  A phase I-II study of intensive-dose adriamycin for advanced breast cancer.

Authors:  R B Jones; J F Holland; S Bhardwaj; L Norton; C Wilfinger; A Strashun
Journal:  J Clin Oncol       Date:  1987-02       Impact factor: 44.544

8.  A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors.

Authors:  R F Ozols; D C Ihde; W M Linehan; J Jacob; Y Ostchega; R C Young
Journal:  J Clin Oncol       Date:  1988-06       Impact factor: 44.544

9.  Dose intensity analysis of chemotherapy regimens in ovarian carcinoma.

Authors:  L Levin; W M Hryniuk
Journal:  J Clin Oncol       Date:  1987-05       Impact factor: 44.544

10.  The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer.

Authors:  M H Bronchud; A Howell; D Crowther; P Hopwood; L Souza; T M Dexter
Journal:  Br J Cancer       Date:  1989-07       Impact factor: 7.640
View more
  6 in total

Review 1.  New perspectives in lung cancer. 4. Haematopoietic growth factors and lung cancer treatment.

Authors:  N Thatcher
Journal:  Thorax       Date:  1992-02       Impact factor: 9.139

2.  [Janus-faced character of chemotherapy: a comment on the Abel theses].

Authors:  D Schmähl
Journal:  Klin Wochenschr       Date:  1991-01-04

3.  The importance of doxorubicin and methotrexate dose intensity in the chemotherapy of osteosarcoma.

Authors:  A Kawai; S Sugihara; T Kunisada; M Hamada; H Inoue
Journal:  Arch Orthop Trauma Surg       Date:  1996       Impact factor: 3.067

4.  Calculation of received dose intensity for combinations of drugs using small-cell lung carcinoma treatment regimens as examples.

Authors:  G L Wampler; J G Fryer
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  An open-label phase 1 dose-escalation clinical trial of a single intravenous administration of gemcitabine in dogs with advanced solid tumors.

Authors:  L Marconato; R Finotello; U Bonfanti; M Dacasto; L Beatrice; S Pizzoni; V F Leone; G Balestra; T Furlanello; C Rohrer Bley; L Aresu
Journal:  J Vet Intern Med       Date:  2015 Mar-Apr       Impact factor: 3.333

Review 6.  Management of chemotherapy dose intensity for metastatic colorectal cancer.

Authors:  Xuelei Chu; Peng Xue; Shijie Zhu
Journal:  Oncol Lett       Date:  2022-03-11       Impact factor: 2.967
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.